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INTRODUCTION
1In this issue of The Journal, Chanda and co-authors  
present data on the clinical utility of risk components of 
the metabolic syndrome (MetS) in predicting the presence 
of the syndrome in patients with Type 2 DM. The 
syndrome was highly prevalent, with 73% of the patients 
meeting its case definition. A large waist circumference 
(WC) was present in 68% of the study population, and 
predicted the presence of the MetS in a majority of them. 
Because of its simplicity in assessment compared to other 
components of the syndrome, the authors recommend use 
of WC as an initial screening test for MetS, especially in 
resource-poor settings. 
But what is the metabolic syndrome? And why should we 
be concerned about it?   
With renewed focus on non-communicable and lifestyle 
diseases around the world, greater efforts are needed for 
early recognition, intervention and public-health 
measures to reduce the burden of risk for chronic diseases. 
The MetS has been described among virtually all 
population groups around the globe, and there is only one 
message: it is not good for health! Understanding it, and 
knowing how to recognise it, thus, makes sense.
In this review, we look at how the case definition of the 
syndrome has evolved over the years, its prevalence and, 
ongoing controversies regarding whether diagnosis of the 
MetS adds any more value to estimates of prospective 
development of its attendant complications than what its 
components are able to predict.       
BACKGROUND 
The concept of metabolic syndrome (MetS) was first 
3introduced by Reaven in 1988 . The syndrome is a 
combination of medical conditions, which, when present 
in an individual, portends increased risk of development 
of type 2 diabetes mellitus (DM) and atherosclerotic 
cardiovascular disease (CVD). It is also known as 
metabolic syndrome X, cardiometabolic syndrome, 
syndrome X, insulin resistance syndrome, and 
Reaven's syndrome (named for Reaven). 
Since its introduction into the medical literature, the MetS 
has excited a lot of research interest as well as debate. 
Various studies have documented the prevalence of the 
syndrome among diabetic and non-diabetic populations 
and evaluated its contribution to all-cause and 
cardiovascular (CV) mortality. However, debate still 
rages whether the syndrome is a distinct entity or simply 
reflects an aggregation of CVD risk factors. In this regard, 
opponents of the syndrome argue that identification of 
individual components of the syndrome is of greater 
clinical utility since these are associated with greater odds 
of prospective development of CVD disease and type 2 
2DM than diagnosis of the MetS .
DEFINITION
Over the years, the definitions of the MetS and cut-off 
points for its components have undergone progressive 
refinement. This has aided and facilitated both clinical 
and epidemiological research on the syndrome. There are 
at present, at least five sets of defining criteria for the 
MetS: the World Health Organisation (WHO) definition 
of 1999; The European Group for the Study of Insulin 
Resistance (EGIR) definition of 1999; The US National 
Cholesterol Education Program (NCEP) Expert Panel 
definition of 2001; the International Diabetes Federation 
(IDF) Consensus worldwide definition of 2006; and the 
harmonised / unified definition of 2010.
The WHO definition
In the quest to establish a uniform definition for the 
syndrome and, thus, a basis for comparison between 
studies, the World Health Organisation (WHO) issued the 
4first working definition of MetS . In the WHO definition, 
MetS was defined as insulin resistance (measured by 
clamp studies) or impaired glucose regulation (impaired 
fasting blood sugar, impaired glucose tolerance, or type 2 
diabetes mellitus) with 2 or more of the following: 1) a 
Blood Pressure (BP) of 140 / 90 mm Hg or higher; (2) 
triglyceride levels of 1.7 mmol/L or higher and / or High 
Density Lipoprotein Cholesterol (HDL-C) levels less 
than 0.9 mmol/L in men and less than 1.0 mmol/L  in 
women; (3) waist-hip ratio greater than 0.90 in men and 
greater than 0.85 in women and /or body mass index 
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(BMI) greater than 30; or (4) microalbuminuria (urinary 
albumin excretion ratio ≥ 20 µg/min or albumin : 
creatinine ratio ≥ 30 mg/g).
The EGIR definition
The European Group for the Study of Insulin Resistance 
(EGIR) proposed several modifications to the WHO 
working definition for the diagnosis of the MetS in non-
5diabetic individuals . The proposed modifications aimed 
to focus attention on criteria that are applicable in 
epidemiologic research and clinical practice. Thus, the 
EGIR proposed use of fasting plasma insulin as a 
surrogate for insulin resistance instead of the euglycemic 
hyper-insulinemic clamp technique used in the WHO 
criteria. Secondly, the EGIR recommended use of fasting 
plasma glucose (≥ 6.1 mmol/L) instead of oral glucose 
tolerance. The EGIR also recommended a change in 
definition of dyslipidemia to triglyceride level higher 
than 2.0mmol/L and/ or HDL-C level less than 1.0 
mmol/L in both men and women; use of waist 
circumference (≥ 94 cm in men and ≥ 80 cm in women) 
instead of waist – hip ratio; and omission of BMI and 
microalbuminuria from the definition.
The NCEP Definition
The third set of diagnostic criteria was issued by the 
National Cholesterol Education Program (NCEP) Expert 
6Panel . The NCEP criteria omit the presence of insulin 
resistance and are based on the presence of 3 or more of 
five components: 1) A BP of 130/ 85 mm Hg or greater; 2) 
Fasting plasma glucose concentration higher than 
6.1mmol/L; 3) triglyceride concentration of 1.69 mmol/L 
or greater; 4) HDL-C concentration less than 1.04 mmol 
5/L; and  waist circumference greater than 102 cm in men 
and 88 cm in women. The NCEP criteria were more 
tailored for clinical use. 
The IDF definition
In 2006, the International Diabetes Federation (IDF) 
issued what they called 'The IDF Consensus worldwide 
7definition of the metabolic' . The definition emphasised 
the importance of central obesity with recognition of 
ethnic variations in waist size. According to the IDF 
definition, a person is deemed to have the MetS if they 
have central obesity (defined as increased waist 
circumference with ethnic specific values) plus any two 
of four other components: 1) raised triglycerides (≥ 1.7 
mmol/L); 2) reduced HDL-C (< 1.03 mmol/L in men and  
(< 1.29 mmol/L in women); 3) raised blood pressure 
(systolic BP ≥ 130 mm Hg or diastolic BP ≥ 85 mm Hg, or 
treatment for previously diagnosed hypertension); and 4) 
raised fasting plasma glucose (FPG  ≥ 5.6 mmol/L). There 
is a general proviso that If body mass index (BMI) is 
>30kg/m², central obesity can be assumed and waist 
circumference does not need to be measured.
The IDF criteria identified three main ethnic specific cut-
off values for waist circumference. These are ≥ 102 cm and 
≥ 88 cm for American men and women, respectively; ≥ 94 
cm and ≥ 80 cm for men and women of European descent, 
respectively; ≥ 90 cm and ≥ 80 cm for men and women, 
respectively of South Asian, Chinese and Japanese 
descent.  For Sub-Saharan Africans, Eastern 
Mediterranean and Middle East (Arab) populations, the 
IDF recommend using the European waist circumference 
cut-off values until more data becomes available while for 
ethnic South and North Americans, the IDF criteria 
recommend use of the South Asian cut-off values.  
The harmonised definition of 2010
Over the years, The IDF definition and the [National 
Cholesterol Education Program Adult Treatment 
Panel] ATP III definition have been the two that have 
been utilized most frequently. However, as more data has 
become available, the definition of the MetS has 
continued to be refined in the quest for a globally accepted 
definition. More recently, different organisations 
comprising the International Diabetes Federation 
(IDF), the National Heart, Lung, and Blood Institute 
(NHLBI), the World Heart Federation, the 
International Atherosclerosis Society, and the 
American Heart Association (AHA) signed to a single 
8definition of the MetS .  This is a further attempt to 
eliminate some of the confusion regarding how to identify 
patients with the syndrome. In particular, the streamlined 
criteria address differences in the previous IDF and the 
ATP III definitions of what constituted abdominal obesity 
as defined by measurements in waist circumference. 
Now, the criteria for elevated waist circumference are 
based on population- and country-specific definitions.
Further, the IDF previously considered elevations in waist 
circumference mandatory when defining metabolic 
syndrome, while the ATP III did not. In the harmonised / 
streamlined definition, waist circumference is just one of 
five criteria that one can use when diagnosing the 
metabolic syndrome. Patients with three of the five 
criteria, including elevated waist circumference, elevated 
triglycerides, reduced HDL-cholesterol levels, elevated 
blood pressure, and elevated fasting-glucose levels, are 
considered to have the syndrome.  The full criterion set of 
the unified / streamlined definition of MetS is shown in 
table 1.  
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Table 1: 2010 Harmonised Criteria for Clinical Diagnosis of the 
Metabolic Syndrome 
PREVALENCE
Life style and dietary habits play a significant role in 
predisposing to development of the MetS. Well-known 
risk factors include mental stress, over-weight and 
obesity, a sedentary life style with low physical activity 
and high caloric intake, and aging. In a number of studies 
among the general population in the Western world, the 
prevalence of MetS has varied between 15% and 30% (9 -
11). Across all population groups, the syndrome 
prevalence is higher among women and increases with 
age. 
Some disease states carry a particularly high risk of the 
syndrome. For example, the large majority 
(approximately 75%) of patients with type 2 DM or 
impaired glucose tolerances, and 50% of patients with 
12coronary heart disease, have MetS . Other non-
communicable disease conditions that carry a high risk of 
the MetS are lipodystrophic disorders, both genetic and 
acquired (such as HIV- related lipodystrophy in patients 
1 2on Highly Active Antiretroviral Therapy) , 
13, 14Schizophrenia and other psychiatric illnesses , and 
15some rheumatic disorders such as psoriatic arthritis .    
THE ONGOING DEBATE
Years after the term metabolic syndrome was first coined, 
controversy continues over the clinical utility and validity 
of the syndrome. The argument over relevance of the 
MetS has set part of the diabetes community against some 
of those in cardiology. On one hand, the American 
Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD) are 
opposed to the use of the term MetS while, on the other 
hand, the National Heart, Lung and Blood Institute 
(NHLBI) and the American Heart Association (AHA) 
16, 17encourage use of the MetS concept . 
Proponents of the MetS argue that the concept is valid 
in that it enables clinicians identify people with this 






Population- and country-specific definitions
Elevated triglycerides (drug 




≥ 1.7 mmol/L (>150 mg/dL)
Reduced HDL cholesterol (drug 
treatment for reduced HDL 
cholesterol is an alternate indicator)
  
< 1.03 mmol/L in (<40 mg/dL) for males 
and < 1.29 mmol/L ( <50 mg/dL) for 
females
Elevated blood pressure (drug 
treatment for elevat ed blood pressure 
is an alternate indicator)
Systolic >130 mm Hg and/or diastolic >85 
mm Hg
Elevated fasting glucose (drug 
treatment for elevated glucose is an 
alternate indicator)
≥ 5.6 mmol/L (>100 mg/dL)
for more aggressive lifestyle advice. Some point out that 
the MetS is particularly applicable in the primary-care 
setting, where recognition of the clustering of risk factors 
can enable a doctor to make the patient more aware of the 
18importance of lifestyle changes .
Opponents of the syndrome argue that diagnosis of the 
MetS does not add any more value to risk prediction than 
its individual components. Therefore, they see no 
additional benefit from identifying these clusters of risk 
factors over measuring and treating the individual risk 
18, 19factors . 
Both sides of the argument have compelling supportive 
evidence. Here is some of that evidence. 
Evidence against
Several studies have shown that presence of the syndrome 
in an individual is no more predictive of prospective 
development of CVD or type 2 DM than individual 
components of the syndrome. In this regard, an analysis of 
two prospective studies by Sattar et al., found that the 
MetS was not associated with cardiovascular (CV) risk in 
the elderly although it was associated with risk of diabetes 
20. 
However, the study revealed that impaired fasting blood 
glucose alone was as strong an indicator of incident 
diabetes as the syndrome. Thus, the authors conclude that 
metabolic syndrome is not necessary to identify those at 
risk of diabetes either. 
Included in this study were participants of 2 prospective 
trials: the Prospective Study of Pravastatin in the 
Elderly at Risk (PROSPER) trial, with 4812 nondiabetic 
men and women aged 72 to 82 years who were followed 
up for 3.2 years, and the British Regional Heart Study 
(BRHS), with 2737 nondiabetic men aged 60 to 79 years, 
followed up for 20 years.
One of the shortcomings of trying to use the MetS as a 
predictive tool has recently been highlighted in an 
analysis to show how information loss occurs during data 
transformation when multiple continuous biological 
21variables are dichotomized . Using the metabolic 
syndrome as a case in point, the authors demonstrate that 
transforming the multiple MetS components into a single 
dichotomous indicator discarded over 98% of the 
potential information contained in the original 
measurements. This is food for thought.
However, the original concept of MetS was not to be a 
diagnostic or prognostic tool. 
In 1977 and 1978, Gerald B. Phillips developed the 
concept that risk factors for MI aggregate in some 
individuals to form a "constellation of abnormalities” 
comprising hypertension, glucose intolerance, 
hyperinsul inemia,  hypercholesterolemia and 
hypertriglyceridemia. It was notable that these 
abnormalities were not only associated with heart disease 
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but also with aging, overweight and obesity, and other 
clinical conditions. From an epidemiology viewpoint, it 
was of great interest to investigate whether these 
conditions had a single underling cause, the identification 
of which could lead to the prevention of cardiovascular 
disease; Phillips hypothesized that this factor was sex 
22hormones .   
In 1988, Gerald M Reaven proposed insulin resistance as 
3the underlying factors . 
Thereafter, the syndrome started to be used as a diagnostic 
tool and arguments ensued. Nevertheless, in recent years, 
new data has emerged which appears to support use of the 
MetS as a predictive tool.   
Evidence in support of the MetS
In a meta-analysis that included 87 studies, with 951 083 
patients, Mottillo et al., showed that patients with 
metabolic syndrome had an approximate twofold increase 
in risk of CVD, cardiovascular mortality, myocardial 
infarction (MI), and stroke and a 1.5-fold increase in risk 
23of all-cause mortality . This is the first meta-analysis to 
establish the cardiovascular risk associated with the MetS 
as defined by the 2004 revised NCEP ATP III criteria of 
the syndrome.  
In another study, an observational longitudinal cohort 
study of 25,471 Japanese men aged 20–61 years with a 
median follow-up of 7.5 years showed that MetS (defined 
by a modified definition of MetS from the Japanese 
Society of Internal Medicine and the NCEP ATPIII) 
associated with increased rates of all-cause mortality, 
Ischemic heart disease (IHD) and CVD. The study also 
demonstrated that any combination of three of the MetS 
components associated with significant increases in rates 
of all-cause mortality and IHD while hypertension in 
combination with dyslipidaemia associated with higher 
rates of CVD (24).  
SHOULD WE BE LOOKING OUT FOR AND 
DIAGNOSING THE MetS?
With all this apparent confusion surrounding the MetS, 
what is the bottom-line? Should we, in our practices, 
endeavour to diagnose the syndrome or be content with 
identifying and treating individual risk components? The 
important message here is that risk factors for CVD and 
type 2 DM do aggregate in some individuals. Recognising 
them is paramount, and that should be our first concern.
USEFULNESS OF ALGORITHMS IN CLINICAL 
DECISION-MAKING
Availability of simple and easily adaptable clinical 
diagnostic algorithms for identifying people with the 
greatest odds of having the syndrome is one step towards 
provision of cost-effective care as it enriches clinical 
decision-making. In this scenario, resources for 
expensive tests (if they cannot be avoided completely) are 
reserved for the further evaluation of only those with the 
greatest probability of having the syndrome. 
Accurate clinical decision making requires, among many 
other factors, an ability to estimate probability of disease 
or prognosis given a particular clinical scenario (history 
and findings of a physical examination). This estimate, 
termed the “pre-test probability”, is modified by the 
results of diagnostic tests to arrive at a “post-test 
probability” of disease. 
In this respect, the information we get from Chanda et al's 
findings is like this: the prevalence of MetS among 
Zambian type 2 diabetics is 73%. Before assessing the 
patient further for other components of the syndrome, this 
(73% or 0.73), is the “pre-test probability” that the patient 
has MetS. Once we have carried out further tests, we can 
estimate the “post-test probability” of the syndrome.  
When the patient also has hypertension, the likelihood 
that they have the MetS rises from 0.73 to 0.85; and to 
0.96 or 0.97 if they also have increased waist 
circumference or have low HDL cholesterol, 
respectively. 
As to which test one should chose, depends on the 
prevalence of the condition under scrutiny in the target 
population as this affects the sensitivity (proportion of 
individuals with an attribute that the test correctly 
identifies) and specificity (proportion of individuals 
without an attribute that the test correctly identifies) of 
the test. 
Again, looking through Chanda et al's results, low HDL 
and raised triglycerides are associated with “post-test 
probabilities” of MetS as high as that of increased waist 
circumference. However, owing to their low prevalence 
among the study population (and by inference, Zambian 
type 2 diabetics in general), screening algorithms based 
on low HDL cholesterol or raised triglycerides would 
miss the diagnosis on many patients with MetS. In this 
regard, the low HDL cholesterol or raised triglycerides 
'tests' would only correctly identify 28% and 42% of 
patients with the MetS, respectively. Thus, they would 
have very high false negative rates of 72% and 58%, 
respectively. On the other hand, screening algorithms 
based on a large waist circumference would correctly 
identify 90% of patients with the MetS; a false negative 
rate of only 10%. This is what makes it a more attractive 
screening test than the other components. 
Therefore, for patients with type 2 DM, we have a simple 
screening tool that should enable us identify those with 
higher likelihood of having the MetS, and target them for 
more intensive lifestyle education and counselling. This 
can be incorporated into routine clinic patient assessment 
guidelines easily and at very minimal cost.      
Medical Journal of Zambia, Vol. 37, No. 3 (2010)
 
REFERENCES
1. H Chanda, P Kelly, B Andrews, S Siziya & S Lakhi. 
Predictive value of Metabolic Syndrome components in 
detecting the syndrome in patients with type 2 Diabetes 
Mellitus. Med J Zambia 2010; 37 (3):  
2. Sattar N, McConnachie A, Shaper AG, et al. Can 
metabolic syndrome usefully predict cardiovascular 
disease and diabetes? Outcome data from two 
prospective studies. Lancet 2008; 371 (9628): 1927 – 
1935.
3. Reaven GM. Banting Lecture 1988: role of insulin 
resistance in human disease. Diabetes 1988; 37: 1595 – 
1607).   
4. Alberti K, Zimmet P, for a WHO Consultation. 
Diagnostic and Classification of Diabetes Mellitus. 
Geneva, Swizerland: World Health Organisation; 1999. 
Definition, Diagnosis and Classification of Diabetes 
Mellitus and its Complications. Part 1.    
5. Balkau B, Charles MA. Comment on the provisional 
report from the WHO consultation: European Group for 
the Study of Insulin Resistance (EGIR). Diabet Med. 
1999; 16: 442 – 443.
6. Executive Summary of the Third Report of the National 
Cholesterol Education Program (NCEP) Expert Panel 
on Detection, Evaluation, and Treatment of High blood 
Cholesterol in Adults (Adult Treatment Panel III). 
JAMA 2001; 285: 2486 – 2497. 
7.  Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a 
new world-wide definition. A Consensus Statement 
from the International Diabetes Federation. Diabet Med 
2006; 23(5): 469-80
8. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing 
the metabolic syndrome. A joint interim statement of the 
International Diabetes Federation Task Force on 
Epidemiology and Prevention; National Heart, Lung, 
and Blood Institute; American Heart Association; 
World Heart Federation; International Atherosclerosis 
Society; and International Association for the Study of 
Obesity. Circulation 2009; 120:1640-1645.
9. Yong- Woo Park, Shankuan Zhu, Latha Palaniappan, et 
al. The Metabolic Syndrome: Prevalence and associated 
risk factor findings in the US population from the Third 
National Health and Nutrition Examination Survey, 
1988 – 1994. Arch Intern Med 2003; 163: 427 – 436. 
10. Gang Hu, Qing Qiao, Jaakko Tuomilehto, Beverly 
Balkan, Knut Borch-Johnsen & Kalevi Pyorala; fot  the 
DECODE study Group. Prevalence of the metabolic 
syndrome and its relation to All-Cause Cardiovascular 
Mortality inNodiabetic European Men and Women.   
Arch Intern Med 2004; 164: 1066 – 1076. 
11. Riedier ND, Clara I, Prevalence of metabolic syndrome 
in the Canadian adult population. CMAJ 2011; 
Available at: http://www.cmaj.ca.  
12. Fauci, Anthony S. (2008). Harrison's principles of 
internal medicine. McGraw-Hill Medical.  
13. John, A. P.; Koloth, R.; Dragovic, M.; Lim, S. C. (2009). 
"Prevalence of metabolic syndrome among Australians 
with severe mental illness". The Medical journal of 
Australia 190 (4): 176–179.
14. Narasimhan M, Raynor JD. Evidence-based 
perspective on metabolic syndrome and use of 
antipsychotics. Drug Benefit Trends. 2010; 22:77 - 88.
15. Quilon A III, Brent L. The primary care physician's 
guide to inflammatory arthritis: diagnosis. J 
Musculoskel Med. 2010;27: 223-231.
16. Richard Kahn, John Buse, Ele Ferrannini, & Michael 
Stern. The Metabolic Syndrome: Time for a Critical 
Appraisal; Joint statement from the American Diabetes 
Association and the European Association for the Study 
of Diabetes. Diabetes Care 2005; 28:2289–2304. 
17. Scott M. Grundy, H. Bryan Brewer, Jr, James I. 
Cleeman, Sidney C. Smith, Jr and Claude Lenfant.  
Definition of Metabolic Syndrome: Report of the 
National Heart, Lung, and Blood Institute/American 
Heart Association Conference on Scientific Issues 
Related to Definition. Circulation 2004, 109:433-438
18. Sue Hughes. Arguments continue over the metabolic 
syndrome. The heart.org July, 2010. Available at 
http://www.theheart.org  
19. Kahn R. Metabolic syndrome – what is the clinical 
usefulness? Lancet 2008 doi: 10.1016/S0140-6736 (08) 
60731-X
20. Sattar N, McConnachie A, Shaper AG et al. Can 
metabolic syndrome usefully predict cardiovascular 
disease and diabetes? Outcome data from two 
prospective studies. Lancet 2008 doi: 10.1016/S0140-
6736 (08) 60602 -9 
21. Jason W. Beckstead & Theresa M Beckie. How Much 
Information Can Metabolic Syndrome Provide? An 
Application of Information Theory. Med Decis Making, 
2011; 31(1): 79-92
22. Phillips GB. "Sex hormones, risk factors and 
cardiovascular disease." The American journal of 
medicine, 1978; 65 (1): 7–11.
23. Mottillo S, Filion KB, Genest J, et al. The metabolic 
syndrome and cardiovascular risk. A systematic review 
and meta-analysis. J Am Coll Cardiol 2010; 56:1113-
1132.
24. Takahisa Kondo, Shigeki Osugi, Keiko Shimokata, et 
al. Metabolic syndrome and all-cause mortality, cardiac 
events, and cardiovascular events: a follow-up study in 
25,471 young- and middle-aged Japanese men.  
European Journal of Cardiovascular Prevention & 
Rehabilitation August 2011 vol. 18 no. 4 574-580.
129
